|Articles|October 1, 2003

Clinical Trials Successful

Auckland, New Zealand - Intradermal injection of a purified cell wall component from heat-killed Mycobacterium vaccae may one day be used to treat children with severe atopic dermatitis, if a clinical program carried out by a New Zealand company continues to be successful.


Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.